Trevi Therapeutics (TRVI) PT Raised to $10 at Needham & Company on Haduvio Data, "Valuation Discounts Potential" Jun 29, 2022 04:14PM
Oppenheimer Reiterates Outperform Rating, $10 Price Target on Trevi Therapeutics (TRVI) on Solidifying PRISM Data Jun 29, 2022 07:58AM
Needham & Company Reiterates Buy Rating, $8 Price Target on Trevi Therapeutics (TRVI) Ahead of Upcoming Trial Data, "Focus Now Turns to The Ph 2b/3 PRISM Trial" May 13, 2022 05:57AM
Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout Mar 18, 2022 06:07AM
Phase 2b/3 PRISM Upcoming Data is Trevi's (TRVI) Most Important Readout, Maintain Buy Into the Analysis - Needham & Company Feb 1, 2022 11:43AM


Jan 6, 2022 01:26PM Trevi Therapeutics' (TRVI) Upcoming PRISM Trial Readout is the Most Important Value-Driver - Needham